Hims & Hers Health forecasted Q1 revenue between $600 million and $625 million, slightly below the Street's $616–650 million estimate, impacted by a $65 million GLP-1 headwind. The company expects GAAP EPS to fall about 83% year-over-year to roughly $0.03, signaling a margin reset already factored into current estimates. Despite this, short interest remains high at about 34% of the float, with 2–3 days to cover, suggesting potential for increased stock volatility. Valuation metrics stand at approximately 2.3 times 2026 sales and 53 times forward P/E, indicating the need for business stabilization and margin recovery to justify current prices.
Hims & Hers is growing internationally and strengthening its healthcare platform beyond longevity therapies, supported by a $400 million JPMorgan receivables facility that enhances financial flexibility for GLP-1 expansion without dilutive equity fin...
The weight loss drug market, driven by GLP-1 therapies, is expected to grow to $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors targeted exposure to this expanding sector, including major pharmaceutical c...
